Gov. Roy Cooper issued a new executive order June 11 extending North Carolina’s mask mandate for many at-risk settings, including public schoo…
Search / 120 results found Showing: 1-10 of 120
featured
RALEIGH — During a Thursday, June 10, media briefing of the Coronavirus Task Force and NC Office of Resiliency and Recovery, Gov. Roy Cooper a…
(The Center Square) – North Carolina will give away $4 million in cash and cover college tuition for people who get vaccinated against COVID-19, Gov. Roy Cooper announced Thursday.
The daily average of first-dose vaccinations each week plummeted to 3,810 in mid-April from a peak of 15,382 in mid-March, according to state data. The average has held relatively steady at about 3,000 first doses per day since May.
Lulu has revealed she had COVID-19 in January and is still feeling the impact of the virus six months later, as she said her symptoms are "lingering".
featured
ASHE COUNTY — Ashe County has continued to see a decrease in COVID-19 as cases stay at a steady total of two active cases, adding to the cumul…
Sharon Stone says 44 million have died from AIDS despite best efforts of those attempting to end the deadly virus- in tearful speech
MORRISVILLE, N.C., June 3, 2021 /PRNewswire/ -- Q2 Solutions and MindX Sciences Inc., a company that works to improve lives through empowering precision medicine approaches to mental health, today announced a partnership, where Q2 Solutions will be conducting genomics laboratory testing services for MindX Sciences blood tests. Initial tests offered by MindX will include mood disorders, such as depression and bipolar disorder, as well as pain, post-traumatic stress disorder (PTSD), suicidality, memory disorders, and longevity.
DURHAM, N.C., May 26, 2021 /PRNewswire/ -- Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients. IN-006 is a potent, neutralizing monoclonal antibody being investigated for the treatment of COVID-19. Initial results of this study are expected in 2022.
Alyssa Milano is encouraging people to get their COVID-19 vaccinations as she continues to battle the long-lasting effects of the virus.
